Biology:Functional selectivity
Functional selectivity (or “agonist trafficking”, “biased agonism”, “biased signaling”, "ligand bias" and “differential engagement”) is the ligand-dependent selectivity for certain signal transduction pathways relative to a reference ligand (often the endogenous hormone or peptide) at the same receptor.[1] Functional selectivity can be present when a receptor has several possible signal transduction pathways. To which degree each pathway is activated thus depends on which ligand binds to the receptor.[2] Functional selectivity, or biased signaling, is most extensively characterized at G protein coupled receptors (GPCRs).[3] A number of biased agonists, such as those at muscarinic M2 receptors tested as analgesics[4] or antiproliferative drugs,[5] or those at opioid receptors that mediate pain, show potential at various receptor families to increase beneficial properties while reducing side effects. For example, pre-clinical studies with G protein biased agonists at the μ-opioid receptor show equivalent efficacy for treating pain with reduced risk for addictive potential and respiratory depression.[1][6] Studies within the chemokine receptor system also suggest that GPCR biased agonism is physiologically relevant. For example, a beta-arrestin biased agonist of the chemokine receptor CXCR3 induced greater chemotaxis of T cells relative to a G protein biased agonist.[7]
Functional vs. traditional selectivity
Functional selectivity has been proposed to broaden conventional definitions of pharmacology.
Traditional pharmacology posits that a ligand can be either classified as an agonist (full or partial), antagonist or more recently an inverse agonist through a specific receptor subtype, and that this characteristic will be consistent with all effector (second messenger) systems coupled to that receptor. While this dogma has been the backbone of ligand-receptor interactions for decades now, more recent data indicates that this classic definition of ligand-protein associations does not hold true for a number of compounds; such compounds may be termed as mixed agonist-antagonists.
Functional selectivity posits that a ligand may inherently produce a mix of the classic characteristics through a single receptor isoform depending on the effector pathway coupled to that receptor. For instance, a ligand can not easily be classified as an agonist or antagonist, because it can be a little of both, depending on its preferred signal transduction pathways. Thus, such ligands must instead be classified on the basis of their individual effects in the cell, instead of being either an agonist or antagonist to a receptor.
It is also important to note that these observations were made in a number of different expression systems and therefore functional selectivity is not just an epiphenomenon of one particular expression system.
Examples
One notable example of functional selectivity occurs with the 5-HT2A receptor, as well as the 5-HT2C receptor. Serotonin, the main endogenous ligand of 5-HT receptors, is a functionally selective agonist at this receptor, activating phospholipase C (which leads to inositol triphosphate accumulation), but does not activate phospholipase A2, which would result in arachidonic acid signaling. However, the other endogenous compound dimethyltryptamine activates arachidonic acid signaling at the 5-HT2A receptor, as do many exogenous hallucinogens such as DOB and lysergic acid diethylamide (LSD). Notably, LSD does not activate IP3 signaling through this receptor to any significant extent. (Conversely, LSD, unlike serotonin, has negligible affinity for the 5-HT2C-VGV isoform, is unable to promote calcium release, and is, thus, functionally selective at 5-HT2C.[8]) Oligomers, specifically 5-HT2A–mGluR2 heteromers, mediate this effect. This may explain why some direct 5-HT2 receptor agonists have psychedelic effects, whereas compounds that indirectly increase serotonin signaling at the 5-HT2 receptors generally do not, for example: selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and medications using 5HT2A receptor agonists that do not have constitutive activity at the mGluR2 dimer, such as lisuride.[9]
Tianeptine, an atypical antidepressant, is thought to exhibit functional selectivity at the μ-opioid receptor to mediate its antidepressant effects.[10][11]
Oliceridine is a μ-opioid receptor agonist that has been described to be functionally selective towards G protein and away from β-arrestin2 pathways.[12] However, recent reports highlight that, rather than functional selectivity or 'G protein bias', this agonist has low intrinsic efficacy.[13] In vivo, it has been reported to mediate pain relief without tolerance nor gastrointestinal side effects.
The delta opioid receptor agonists SNC80 and ARM390 demonstrate functional selectivity that is thought to be due to their differing capacity to cause receptor internalization.[14] While SNC80 causes delta opioid receptors to internalize, ARM390 causes very little receptor internalization.[14] Functionally, that means that the effects of SNC80 (e.g. analgesia) do not occur when a subsequent dose follows the first, whereas the effects of ARM390 persist.[14] However, tolerance to ARM390's analgesia still occurs eventually after multiple doses, though through a mechanism that does not involve receptor internalization.[14] Interestingly, the other effects of ARM390 (e.g. decreased anxiety) persist after tolerance to its analgesic effects has occurred.[14]
An example of functional selectivity to bias metabolism was demonstrated for an electron transfer protein cytochrome P450 reductase (POR) with binding of small molecule ligands shown to alter the protein conformation and interaction with various redox partner proteins of POR.[15]
See also
References
- ↑ 1.0 1.1 Smith, Jeffrey S.; Lefkowitz, Robert J.; Rajagopal, Sudarshan (2018-01-05). "Biased signalling: from simple switches to allosteric microprocessors". Nature Reviews. Drug Discovery 17 (4): 243–260. doi:10.1038/nrd.2017.229. ISSN 1474-1784. PMID 29302067.
- ↑ Simmons MA (June 2005). "Functional selectivity, ligand-directed trafficking, conformation-specific agonism: what's in a name?". Mol. Interv. 5 (3): 154–7. doi:10.1124/mi.5.3.4. PMID 15994454.
- ↑ Bock, Andreas; Merten, Nicole; Schrage, Ramona; Dallanoce, Clelia; Bätz, Julia; Klöckner, Jessica; Schmitz, Jens; Matera, Carlo et al. (2012). "The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling". Nature Communications 3 (1): 1044. doi:10.1038/ncomms2028. ISSN 2041-1723. PMID 22948826. Bibcode: 2012NatCo...3.1044B.
- ↑ Matera, Carlo; Flammini, Lisa; Quadri, Marta; Vivo, Valentina; Ballabeni, Vigilio; Holzgrabe, Ulrike; Mohr, Klaus; De Amici, Marco et al. (2014). "Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: Synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity". European Journal of Medicinal Chemistry 75: 222–232. doi:10.1016/j.ejmech.2014.01.032. ISSN 0223-5234. PMID 24534538.
- ↑ Cristofaro, Ilaria; Spinello, Zaira; Matera, Carlo; Fiore, Mario; Conti, Luciano; De Amici, Marco; Dallanoce, Clelia; Tata, Ada Maria (2018). "Activation of M2 muscarinic acetylcholine receptors by a hybrid agonist enhances cytotoxic effects in GB7 glioblastoma cancer stem cells". Neurochemistry International 118: 52–60. doi:10.1016/j.neuint.2018.04.010. ISSN 0197-0186. PMID 29702145.
- ↑ Manglik, Aashish; Lin, Henry; Aryal, Dipendra K.; McCorvy, John D.; Dengler, Daniela; Corder, Gregory; Levit, Anat; Kling, Ralf C. et al. (8 September 2016). "Structure-based discovery of opioid analgesics with reduced side effects". Nature 537 (7619): 185–190. doi:10.1038/nature19112. ISSN 1476-4687. PMID 27533032. Bibcode: 2016Natur.537..185M.
- ↑ Smith, Jeffrey S.; Nicholson, Lowell T.; Suwanpradid, Jutamas; Glenn, Rachel A.; Knape, Nicole M.; Alagesan, Priya; Gundry, Jaimee N.; Wehrman, Thomas S. et al. (2018-11-06). "Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation". Science Signaling 11 (555): eaaq1075. doi:10.1126/scisignal.aaq1075. ISSN 1937-9145. PMID 30401786.
- ↑ Backstrom, Jon R; Chang, Mike S; Chu, Hsin; Niswender, Colleen M; Sanders-Bush, Elaine (Aug 1, 1999). "Agonist-Directed Signaling of Serotonin 5-HT2C Receptors: Differences Between Serotonin and Lysergic Acid Diethylamide (LSD)". Neuropsychopharmacology 21 (2): 77–81. doi:10.1016/S0893-133X(99)00005-6. PMID 10432492.
- ↑ "Functional selectivity and classical concepts of quantitative pharmacology". J. Pharmacol. Exp. Ther. 320 (1): 1–13. January 2007. doi:10.1124/jpet.106.104463. PMID 16803859. https://cdr.lib.unc.edu/record/uuid:90abb8bf-82e2-46c6-8880-1843eb03645d.
- ↑ "The Behavioral Effects of the Antidepressant Tianeptine Require the Mu Opioid Receptor". Neuropsychopharmacology 42 (10): 2052–2063. 2017. doi:10.1038/npp.2017.60. PMID 28303899.
- ↑ Cavalla, D; Chianelli, F (August 2015). "Tianeptine prevents respiratory depression without affecting analgesic effect of opiates in conscious rats.". European Journal of Pharmacology 761: 268–272. doi:10.1016/j.ejphar.2015.05.067. PMID 26068549.
- ↑ "A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine". Journal of Pharmacology and Experimental Therapeutics 344 (3): 708–17. March 2013. doi:10.1124/jpet.112.201616. PMID 23300227.
- ↑ Gillis, A; Gondin, AB; Kliewer, A; Sanchez, J; Lim, HD; Alamein, C; Manandhar, P; Santiago, M et al. (31 March 2020). "Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists.". Science Signaling 13 (625): eaaz3140. doi:10.1126/scisignal.aaz3140. PMID 32234959. https://nottingham-repository.worktribe.com/output/4193457.
- ↑ 14.0 14.1 14.2 14.3 14.4 Pradhan, Amynah A.; Befort, Katia; Nozaki, Chihiro; Gavériaux-Ruff, Claire; Kieffer, Brigitte L. (October 2011). "The delta opioid receptor: an evolving target for the treatment of brain disorders". Trends in Pharmacological Sciences 32 (10): 581–590. doi:10.1016/j.tips.2011.06.008. PMID 21925742.
- ↑ Jensen, Simon Bo; Thodberg, Sara; Parween, Shaheena; Moses, Matias E.; Hansen, Cecilie C.; Thomsen, Johannes; Sletfjerding, Magnus B.; Knudsen, Camilla et al. (December 2021). "Biased cytochrome P450-mediated metabolism via small-molecule ligands binding P450 oxidoreductase" (in en). Nature Communications 12 (1): 2260. doi:10.1038/s41467-021-22562-w. ISSN 2041-1723. PMID 33859207. Bibcode: 2021NatCo..12.2260J.
Further reading
- "Biased Ligands of G Protein-Coupled Receptors: Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential". J. Med. Chem. 61 (22): 9841–9878. July 2018. doi:10.1021/acs.jmedchem.8b00435. PMID 29939744.
- "A Pluridimensional View of Biased Agonism". Mol. Pharmacol. 90 (5): 587–595. 2016. doi:10.1124/mol.116.105940. PMID 27638872.
- "Refining Efficacy: Exploiting Functional Selectivity for Drug Discovery". Pharmacology of G Protein Coupled Receptors. Advances in Pharmacology. 62. 2011. pp. 79–107. doi:10.1016/B978-0-12-385952-5.00009-9. ISBN 9780123859525.
- "Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology". Circ. Res. 109 (2): 205–16. July 2011. doi:10.1161/CIRCRESAHA.110.231308. PMID 21737816.
- Kenakin T (1995). "Agonist-Receptor Efficacy. II. Agonist Trafficking of Receptor Signals". Trends Pharmacol Sci 16 (7): 232–8. doi:10.1016/S0165-6147(00)89032-X. PMID 7667897. https://cdr.lib.unc.edu/record/uuid:e3546176-4b38-4c42-bfec-8990d429363f.
 |  |
